Ashburn, VA, November 8, 2017 — Aperiomics, a biotechnology company that harnesses the power of deep next-generation sequencing to identify all known pathogens (bacteria, virus, fungi or parasite) in a single test, today announced that it is partnering with Milenia Labs to further expand its international outreach. Milenia, based in the North Central part of Mexico, operates diagnostic labs in Mexico, South and Central America with providers mainly from the United States, Canada and also from Germany, Switzerland, and France.

Milenia will send biological samples from its customers to Aperiomics for full analysis and identification of all known pathogens. “Aperiomics provides a truly unique service; nothing like it exists anywhere,” said Milenia CEO and Founder Dr. Salvador Cardona. “Their team will give us extremely accurate assessments to help our patients and their doctors greatly shorten the time that it takes to identify the cause of infectious diseases.”

Aperiomics CEO and co-founder Dr. Crystal Icenhour, said, “This is a big step forward for both companies. We’re very excited to expand our international reach through Milenia and be able to help its customers solve difficult medical cases quickly and efficiently.”

This has been a big year for both companies. Aperiomics has grown its customer base more than ten-fold during 2017. With each customer (or doctor) representing multiple patients, the company has seen a dramatic increase in the number of patients it serves. Revenue over the first six months alone was higher than the entirety of the company’s revenue since it began operations in 2014. Milenia is on track to expand to additional markets in Panama and Chile as it is already present in Colombia, Ecuador, and Venezuela. Over the next five years it plans to be present in every Latin American city with a population in excess of one million.

About Aperiomics

The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test. Clinicians and patients call on Aperiomics to aid in the identification of infectious diseases that other tests cannot identify or would require a multitude of tests and an idea of what to look for. Through next-generation sequencing of the DNA or RNA in a sample, a complete genetic fingerprint is created and run through a proprietary data analysis algorithm to profile the entire sample. The Aperiomics Microbial Database™- is the most comprehensive database of microorganisms, including the world’s largest collection of pathogens. This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others. Aperiomics was named Life Sciences Innovators of the year in 2016 and a finalist in the 2017 Greater Washington Innovation Awards. For more information, visit www.aperiomics.com or call (703) 229-0406.